{"entity":{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","aka":[],"tldr":"Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.","summary":"Aleksandar Sekulic is a dermatologist and physician-scientist at Mayo Clinic in Arizona. He was first author of the 2012 New England Journal of Medicine report of ERIVANCE BCC, the phase 2 trial in which the Hedgehog pathway inhibitor vismodegib produced responses in most patients with locally advanced and in a third of those with metastatic basal cell carcinoma, the basis of the drug's approval.","asOf":"2026-09-18","links":[],"tags":["skin","targeted-therapy","trialist"],"related":[],"cancers":["locally-advanced-bcc","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic-arizona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-erivance-vismodegib-sekulic-nejm-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"Dermatologist, Mayo Clinic Comprehensive Cancer Center in Arizona","institutionId":"mayo-clinic-arizona","specialisms":["Basal cell carcinoma","Hedgehog pathway inhibitors","Skin cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sekulic%5BAuthor%5D"}],"papers":[]},"route":"/people/aleksandar-sekulic/","neighbours":{"cancer":[{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"institution":[{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/"}],"paper":[{"id":"paper-erivance-vismodegib-sekulic-nejm-2012","kind":"paper","name":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","route":"/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/"}]}}